Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREMIER: Early sacubitril valsartan in hospitalized patients with worsening heart failure
jRCTs021210046Completed
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of sacubitril + valsartan in heart failure (HF) (2 arms), sponsored by Novartis. Primary endpoint: Primary: Group ratio of percent change in geometric mean NT-proBNP at 8 weeks. Started Dec 2021; status: completed.
02
Drugs
sacubitril + valsartan
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on jRCTs021210046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021210046.